This app is specifically intended for participants in the GSK 221458 study only.

It contains Televisit functionality and allows participants to complete questionnaires.

The study is a Phase 1, first-time-in-human, three-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active systemic lupus erythematosus (Part B), and healthy participants of Chinese and Japanese descent (Part C).

(Televisit tasks are not enabled by default and may be enabled as needed, by study officials.)